Ex-Gilead Executive's Novel-Drug Startup Targets $1 Billion IPO Valuation
A startup founded by a onetime Gilead Sciences executive is pursuing an initial public offering at a $1 billion valuation, The Business Journals reports.
Topic
Gilead
Topic
Topic
Topic
A startup founded by a onetime Gilead Sciences executive is pursuing an initial public offering at a $1 billion valuation, The Business Journals reports.